Management of Palpitations in Elderly Patients

Introduction to Beta Blockers

The European Society of Cardiology and the American College of Cardiology recommend starting with a low dose of beta blockers, such as bisoprolol 1.25 mg or metoprolol succinate 12.5 mg, and gradually titrating the dose at 1-2 week intervals based on symptom control and tolerability in elderly patients with palpitations 1, 2
The American College of Cardiology suggests maintaining current angiotensin receptor blocker (ARB) therapy, such as valsartan, as it complements beta blocker therapy in elderly patients with palpitations 2

Elderly patients have reduced drug clearance, requiring lower initial doses of beta blockers due to altered pharmacokinetics 3
The European Society of Cardiology recommends monitoring standing blood pressure during dose titration to minimize the risk of orthostatic hypotension in elderly patients 1

The initial dose of bisoprolol should be 1.25 mg once daily, with a target dose of 10 mg once daily, and metoprolol succinate (extended-release) should be started at 12.5-25 mg once daily, with a target dose of 200 mg once daily in elderly patients with palpitations 1, 2
The recommended dosage for nebivolol is 5-40 mg once daily, with an initial dose of 5 mg and a target dose of 40 mg once daily 4, 5, 6
Carvedilol is preferred in heart failure with reduced ejection fraction (HFrEF) at a dose of 12.5-50 mg twice daily, with demonstrated 65% mortality reduction in heart failure trials 7, 6

The European Society of Cardiology suggests monitoring blood pressure, heart rate, and symptoms of bradycardia during beta blocker therapy in elderly patients with palpitations 1
The American College of Cardiology recommends reducing the dose of beta blockers if the heart rate drops below 50 bpm with symptoms in elderly patients with palpitations 2
Beta blockers should be used with caution in patients with diabetes, and blood glucose levels should be monitored 8, 5, 6

Beta blockers are contraindicated in patients with asthma, severe bronchial disease, symptomatic bradycardia, hypotension, and reactive airways disease for non-cardioselective beta blockers 3, 4, 5, 6
Atenolol should not be used as it is less effective than placebo in reducing cardiovascular events 6
Beta blockers with intrinsic sympathomimetic activity (acebutolol, penbutolol, pindolol) should be avoided, especially in patients with ischemic heart disease or heart failure 5, 6
The American Heart Association advises to use beta blockers with caution in patients with diabetes, and to avoid combining with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) due to risk of bradycardia 7

The American College of Cardiology recommends that beta blockers can be effectively combined with diuretics to enhance antihypertensive effect, and with dihydropyridine calcium channel blockers for patients with persistent angina despite beta-blocker therapy 6
The use of beta blockers with non-dihydropyridine calcium channel blockers (e.g. diltiazem, verapamil) should be avoided due to the risk of bradycardia and heart block 8, 5, 6

Beta blockers should not be abruptly discontinued, as this may lead to exacerbation of angina, myocardial infarction, and arrhythmias, and instead should be tapered gradually by reducing dose by half every week for 3 weeks, monitoring blood pressure and heart rate during tapering 9, 10, 6
In cases of worsening heart failure symptoms, the dose of diuretics should be doubled and/or the dose of the beta blocker should be reduced by half 11, 6
In cases of bradycardia, the dose of the beta blocker should be reduced by half if the heart rate is <50 bpm with symptoms, and other medications that decrease heart rate should be reviewed 11
In cases of symptomatic hypotension, the need for nitrates or other vasodilators should be reassessed, and the dose of diuretics should be reduced if there is no congestion 11

In heart failure patients, carvedilol, metoprolol succinate, bisoprolol, and nebivolol have demonstrated mortality benefits 7
In post-MI patients, beta blockers reduced all-cause mortality by 23% 6
Beta blockers are not first-line treatment for uncomplicated hypertension, but are useful in patients with comorbidities such as coronary artery disease, post-myocardial infarction, heart failure with reduced ejection fraction (HFrEF), and stable ischemic heart disease (SIHD) 8, 9, 5, 6